tiprankstipranks
Roivant Sciences board approves of repurchase program up to $1.5B
PremiumThe FlyRoivant Sciences board approves of repurchase program up to $1.5B
16d ago
Roivant Sciences announces NEPTUNE study met primary efficacy endpoint
PremiumThe Fly
Roivant Sciences announces NEPTUNE study met primary efficacy endpoint
16d ago
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
PremiumPress Releases
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
16d ago
Sunrun to replace PGT Innovations in the S&P 600 at open on 4/1
PremiumThe FlySunrun to replace PGT Innovations in the S&P 600 at open on 4/1
22d ago
Roivant Sciences to replace Sunrun in the S&P 400 at open on 4/1
PremiumThe Fly
Roivant Sciences to replace Sunrun in the S&P 400 at open on 4/1
22d ago
JPMorgan reiterates Overweight ratings on Roivant, Immunovant
PremiumThe Fly
JPMorgan reiterates Overweight ratings on Roivant, Immunovant
23d ago
Wolfe starts Roivant at Outperform, notes robust balance sheet
PremiumThe FlyWolfe starts Roivant at Outperform, notes robust balance sheet
2M ago
Roivant Sciences initiated with an Outperform at Wolfe Research
PremiumThe Fly
Roivant Sciences initiated with an Outperform at Wolfe Research
2M ago
Roivant Sciences price target lowered to $17 from $18 at H.C. Wainwright
PremiumThe Fly
Roivant Sciences price target lowered to $17 from $18 at H.C. Wainwright
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100